Ovid Therapeutics Inc. (OVID)Healthcare | Biotechnology | New York, United States | NasdaqCM
2.20 USD
-0.22
(-8.940%) ⇩
(Oct. 13, 2026, 3:49 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:11 a.m. EDT
The investment case here is a stark dichotomy between aggressive retail sentiment and deteriorating corporate reality. On the surface, the stock looks like a classic 'penny stock' momentum play; analysts are issuing 'strong buy' ratings with targets nearly four times the current price, and options traders are pouring capital into $5 and $7.50 calls, betting on a massive recovery. However, the underlying business is failing. Revenue has collapsed by 88% year-over-year, and the company is burning cash aggressively with no path to profitability visible in the forward estimates. The balance sheet, while currently liquid due to cash holdings, is propped up by a massive current ratio that masks the operational rot. The recent price action shows the stock struggling to hold gains, trading below its 50-day average despite the hype. While the options flow suggests a crowd willing to chase a miracle turnaround, the fundamentals—shrinking top line, negative returns on equity, and a history of multi-year decline—make this a dangerous speculative trap rather than a viable investment. The 'strong buy' consensus appears to be pricing in a binary event that hasn't happened yet, ignoring the fact that the company is actively losing ground in every metric that matters for a biotech firm. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.059608 |
| AutoETS | 0.093026 |
| AutoARIMA | 0.093027 |
| MSTL | 0.096115 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.493 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.058 |
| Revenue per Share | 0.013 |
| Market Cap | 428,678,784 |
| Forward P/E | -5.85 |
| Beta | 0.23 |
| Website | https://www.ovidrx.com |
As of Oct. 10, 2026, 9:11 a.m. EDT: Speculators are overwhelmingly bullish on upside potential, evidenced by massive open interest in out-of-the-money calls at the $5.00 and $7.50 strikes compared to negligible put activity. This heavy call positioning suggests a bet on a significant rally to double the current price, while the lack of protective puts indicates a willingness to take downside risk in exchange for asymmetric upside exposure.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3771429 |
| Address1 | Hudson Commons |
| Address2 | 441 9th Avenue 14th Floor |
| All Time High | 15.929 |
| All Time Low | 0.243 |
| Ask | 2.4 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,398,950 |
| Average Daily Volume3 Month | 1,568,195 |
| Average Volume | 1,568,195 |
| Average Volume10Days | 1,398,950 |
| Beta | 0.23 |
| Bid | 1.73 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.136 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.195 |
| Current Ratio | 12.386 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.415 |
| Day Low | 2.18 |
| Debt To Equity | 6.058 |
| Display Name | Ovid Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -57,974,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.316 |
| Enterprise To Revenue | 231.31 |
| Enterprise Value | 366,163,840 |
| Eps Current Year | -0.3775 |
| Eps Forward | -0.375 |
| Eps Trailing Twelve Months | -0.22 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 646 661 4027 |
| Fifty Day Average | 2.6457 |
| Fifty Day Average Change | -0.45070004 |
| Fifty Day Average Change Percent | -0.17035191 |
| Fifty Two Week Change Percent | 37.71429 |
| Fifty Two Week High | 3.105 |
| Fifty Two Week High Change | -0.9100001 |
| Fifty Two Week High Change Percent | -0.2930757 |
| Fifty Two Week Low | 1.18 |
| Fifty Two Week Low Change | 1.015 |
| Fifty Two Week Low Change Percent | 0.86016953 |
| Fifty Two Week Range | 1.18 - 3.105 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,991,000,000 |
| Float Shares | 163,388,140 |
| Forward Eps | -0.375 |
| Forward P E | -5.853333 |
| Free Cashflow | -33,121,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | -0.21500015 |
| Fullday Change Percent | -8.939714 |
| Fullday Price | 2.195 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 1,583,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06724 |
| Held Percent Institutions | 0.80424005 |
| Implied Shares Outstanding | 195,297,857 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. |
| Long Name | Ovid Therapeutics Inc. |
| Market | us_market |
| Market Cap | 428,678,784 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_288870432 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,477,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 503,692,702 |
| Number Of Analyst Opinions | 10 |
| Open | 2.41 |
| Operating Cashflow | -54,773,000 |
| Operating Margins | -21.006819 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 646 661 7661 |
| Previous Close | 2.41 |
| Price Eps Current Year | -5.8145695 |
| Price Hint | 4 |
| Price To Book | 1.9322182 |
| Price To Sales Trailing12 Months | 270.8015 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.745 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.21500015 |
| Regular Market Change Percent | -8.939714 |
| Regular Market Day High | 2.415 |
| Regular Market Day Low | 2.18 |
| Regular Market Day Range | 2.18 - 2.415 |
| Regular Market Open | 2.41 |
| Regular Market Previous Close | 2.41 |
| Regular Market Price | 2.195 |
| Regular Market Time | 1,791,920,999 |
| Regular Market Volume | 1,225,872 |
| Return On Assets | -0.23456 |
| Return On Equity | -0.25964 |
| Revenue Growth | -0.883 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 195,297,857 |
| Shares Percent Shares Out | 0.096999995 |
| Shares Short | 18,948,082 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 20,674,725 |
| Short Name | Ovid Therapeutics Inc. |
| Short Percent Of Float | 0.111099996 |
| Short Ratio | 11.15 |
| Source Interval | 15 |
| State | NY |
| Symbol | OVID |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.024 |
| Target Median Price | 5.12 |
| Total Cash | 117,219,000 |
| Total Cash Per Share | 0.6 |
| Total Debt | 12,715,000 |
| Total Revenue | 1,583,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.32035 |
| Two Hundred Day Average Change | -0.12535 |
| Two Hundred Day Average Change Percent | -0.054022025 |
| Type Disp | Equity |
| Volume | 1,225,873 |
| Website | https://www.ovidrx.com |
| Zip | 10,001 |